Table 1.

NVP-AUY922 IC50 concentrations in gastric cancer cell lines

Cell lineHistologyHER2 amplification statusNVP-AUY922 IC50g (mean ± SE, nmol/L)
NCI N87aGastricAmplified0.70 ± 0.34
FU 97GastricNot amplified2.68 ± 0.01
OE33GastricAmplified2.84 ± 0.00
NUGC 3GastricNot amplified4.41 ± 0.65
MKN74GastricNot amplified5.42 ± 0.60
MKN 1bGastricNot amplified5.88 ± 0.93
MKN45GastricNot amplified6.43 ± 0.10
OE19aGastricAmplified6.64 ± 0.91
AGScGastricNot amplified7.71 ± 1.08
SNU 5GastricNot amplified7.75 ± 1.22
SNU 1GastricNot amplified8.37 ± 0.62
IM95dGastricNot amplified9.40 ± 3.96
KATO IIIGastricNot amplified17.14 ± 5.03
IM98mGastricNot amplified23.08 ± 0.22
SNU 16GastricNot amplified78.60 ± 27.06
NUGC 4GastricNot amplified148.13 ± 48.55
  • aNCI-N87 and OE19 had 23.88% ± 1.77% and 40.92% ± 1.17% growth inhibition when treated with 10 μg/mL of trastuzumab. OE33 had no growth inhibition when treated with the same concentration of trastuzumab.

  • bPI3K mutation: c.1633G>A.

  • cPI3K mutation: c.1357G>A.

  • dPI3K mutation: c.1624G>A.